Gerd Burmester, MD, professor of medicine, at Charité-University, Berlin, Germany, discusses results from the SARIL-RA-MONARCH trial (ClinicalTrials.gov Identifier: NCT02332590), evaluating the comparative efficacy of sarilumab monotherapy and adalimumab monotherapy in patients who were inadequate responders or intolerant to methotrexate. 

Follow Rheumatology Advisor’s continuing conference coverage by clicking here